Romania nears deal to form government after weeks of deadlock
BUCHAREST, Romania - Romania's pro-European parties closed in on an agreement to form a government as leaders set out to rein in a budget deficit that's become the widest in the European Union.
The National Liberal Party put forward its leader, Ilie Bolojan, to be prime minister. The long-dominant Social Democrats, which declined to designate a candidate, said a coalition accord between the main parties and two smaller partners is likely as negotiators put the final touches on a deal.
"It's hard to say at this moment that we're at a 100% probability for a four-party ruling coalition, but I think we're at about 80-90%," Sorin Grindeanu, the Social Democrats' interim leader, told reporters in Bucharest.
President Nicusor Dan, a centrist who beat back a far-right challenge to win the country's highest office last month, is expected to nominate a prime minister on Friday, according to people familiar with the plans who asked not to be identified as talks take place behind closed doors.
Once designated, the premier will have 10 days to form a Cabinet and seek a vote of confidence in parliament.
Romania was plunged into its gravest political crisis since the fall of communism late last year with the shock victory of an ultranationalist outsider in a presidential vote, which was subsequently annulled and rescheduled for May. Dan's victory signaled that voters want to hew to the nation's pro-European path amid growing geopolitical turmoil.
Dan has made clear that the government's top priority must be to scale back the budget deficit. The parties are seeking to overcome deep differences over how to address a fiscal gap that accounted for about 9% of economic output last year.
But the budget remedy, including impending spending cuts and tax increases, is likely to carry political risks - and be exploited by a surging far right. George Simion, who leads the ultranationalist Alliance for the Union of Romanians, scored a decisive first-round victory in the presidential contest on May 4, prompting the resignation of then-Prime Minister Marcel Ciolacu. But he went down to defeat two weeks later.
Romanian assets have rebounded since Dan's victory, with the yield on the country's 10-year domestic bonds falling by about a percentage point from over a two-year high last month. The yield now trades at 7.4%, the lowest level since April - but still the steepest borrowing costs in the E.U.
The four pro-European parties control 60% of the seats in parliament. The Social Democrats, who won an election in December and have the largest number of lawmakers in the chamber, will join the Liberals, the anti-corruption Save Romania Union and a party representing ethnic Hungarians.
Grindeanu said the Social Democrats will deliberate on whether to join the coalition on Friday, expressing optimism that members will sign off. The party had raised the prospect of supporting a minority Liberal-led government without joining the coalition, but opted for a broader agreement.
Romania, a member of the E.U. as well as NATO, has pledged to lay out a detailed plan to narrow the deficit to the European Commission by the end of this month. The E.U.'s executive arm has so far refrained from suspending E.U. funds, despite Romania's status under a so-called excessive deficit procedure. It instead called on Bucharest to adopt urgent measures.
----------
-With assistance from Peter Laca.
Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
LegalBison Establishes Southeast Asia Presence with New Malaysian Office
New Kuala Lumpur office strengthens LegalBison's regional reach and enhances regulatory support across Asia. Kuala Lumpur, Malaysia--(Newsfile Corp. - June 20, 2025) - LegalBison, a global regulatory advisory firm specializing in the FinTech and crypto sectors, has officially opened its new office in Kuala Lumpur, marking the company's first physical expansion into Asia and reinforcing its long-term growth strategy in emerging financial markets. LegalBison To view an enhanced version of this graphic, please visit: This milestone follows the success of LegalBison's European headquarters in Tallinn, Estonia, and represents a strategic effort to better serve clients throughout Southeast Asia-including Malaysia, Singapore, Indonesia, Thailand, and beyond. "Availability for international clients has always been one of LegalBison's key strengths," said Sabir Alijev, Chief Product Officer at LegalBison. "With our new presence in Malaysia, we now have a bird's-eye view of the local regulatory landscape and are ready to deliver timely, regionally tailored solutions." Kuala Lumpur was selected for its robust regulatory institutions, economic stability, and position as a rising hub for digital finance in Asia. Establishing operations in Malaysia allows LegalBison to deepen relationships with local partners and clients while offering more agile support in licensing, AML/KYC compliance, cross-border banking, and corporate structuring. LegalBison's move reflects the growing demand for localized compliance expertise in Asia's fast-evolving financial landscape. The Malaysian team will collaborate closely with LegalBison's Estonia office to provide seamless advisory services across time zones, ensuring clients benefit from both global perspective and local insight. By anchoring its Asia-Pacific strategy in Kuala Lumpur, LegalBison positions itself as a trusted partner to startups, growth-stage firms, and enterprises navigating complex cross-border regulatory environments. LegalBison is now actively onboarding clients across Southeast Asia and is open to strategic partnerships throughout the region and globally. For media inquiries or more information, please visit or contact pr@ About LegalBison Founded in 2020, LegalBison is a regulatory and legal advisory firm headquartered in Tallinn, Estonia. The firm supports companies in the FinTech, crypto, and high-compliance sectors with services including licensing, compliance, banking solutions, and international corporate structuring. LegalBison provides tailored, cross-border support to help businesses navigate complex regulatory environments worldwide. Media Contact LegalBison PR Teampr@ 20 4577 To view the source version of this press release, please visit
Yahoo
26 minutes ago
- Yahoo
NBA star Durant takes minority PSG stake
Kevin Durant, who won gold in the Paris 2024 basketball, has taken a stake in the city's best-known football club Paris Saint-Germain (Aris MESSINIS) Basketball star Kevin Durant has taken a minority stake in Paris Saint-Germain, the European champions announced Friday, without saying how many shares the power forward had acquired. The club said in a statement that owners Qatar Sports Investment (QSI) had "signed an investment and strategic partnership agreement with Kevin Durant, one of the most decorated US basketball players of all time and a leading investor in sports and entertainment properties." Advertisement It said Durant would acquire the stake "via his media and investment arm Boardroom". The club said QSI would cooperate with Boardroom "on a wide-series of commercial, investment, and content initiatives" including merchandise, media content US and international strategy and "potential Basketball/Multi-Sport expansion." "With Kevin, we look forward to developing ambitious initiatives that will drive the continued global growth of Paris Saint-Germain and QSI," said Nasser Al-Khelaifi, Chairman of QSI. Durant, 36, is a power forward with the Phoenix Suns. He won two NBA titles with the Golden State Warriors and has four Olympic gold medals, the last from the 2024 Paris Games. Advertisement He said in the PSG statement that PSG and Paris were "a Club and a city that is so close to my heart. This club has big plans ahead, and I can't wait to be a part of the next phase of growth." eba/pb/pi
Yahoo
an hour ago
- Yahoo
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the European Union. Positive opinion is based on results from the pivotal Phase III ARANOTE trial. Pending approval, this broadened indication would give doctors the option to use darolutamide plus ADT, with or without chemotherapy (docetaxel), offering greater flexibility to tailor treatment plans to meet mHSPC patients' needs. Orion's collaboration partner Bayer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) for marketing authorisation in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The CHMP recommendation is based on positive results from the pivotal Phase III ARANOTE trial which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. A final decision on marketing authorisation from the European Commission is anticipated in the coming months. The U.S. Food and Drug Administration (FDA) recently approved darolutamide in combination with ADT for mHSPC in June 2025, making it the first and only in the US and FDA-approved ARi for the treatment of patients with mHSPC, in combination with ADT, with or without chemotherapy. Darolutamide, under the brand name Nubeqa®, is approved in over 85 countries for use with ADT and docetaxel in mHSPC, and with ADT alone in non-metastatic castration-resistant prostate cancer (nmCRPC) in patients who are at high risk of developing metastatic disease. Darolutamide is developed jointly by Orion and Bayer. Prostate cancer is the second most common cancer and the fifth most common cause of cancer death in men worldwide. In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 In Europe, there were almost 474,000 estimated new cases of prostate cancer in 2022 with approximately 115,000 deaths. 2 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.3 About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS, measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in radiological progression-free survival (rPFS) were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans, support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile, in both mHSPC registrational studies where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as a treatment for localized prostate cancer in combination with radiotherapy. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.4,5,6 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: June 2025. Ferlay J et al. 2024. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available at: Accessed June 2025.. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
